National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Parathyroid Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 01/03/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Localized Parathyroid Cancer






Metastatic Parathyroid Cancer






Recurrent Parathyroid Cancer






Get More Information From NCI






Changes to This Summary (01/03/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Localized Parathyroid Cancer

Current Clinical Trials

Treatment options:[1-4]

  1. The initial operation should include an en bloc resection of the tumor that takes care to avoid rupture of the tumor capsule and to ensure that the margins are free of tumor. This procedure will involve a parathyroidectomy, typically an ipsilateral thyroidectomy (thyroid lobectomy), and possibly resection of adjacent cervical muscles, paratracheal tissues, and the recurrent laryngeal nerve, if involved. Lymphadenectomy, beyond that necessary to achieve an en bloc excision of the primary malignancy, is not indicated unless enlarged or firm nodes clinically indicate the presence of nodal disease. Local recurrence may be minimized by this en bloc resection approach. Preoperative medical management to lower elevated calcium levels and to correct other metabolic disturbances that are due to hyperparathyroidism is critical.


  2. Surgery followed by radiation therapy.[4-6]


  3. Radiation therapy.


Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with localized parathyroid cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Fraker DL: Parathyroid Tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2005, pp 1521-27. 

  2. Sandelin K, Auer G, Bondeson L, et al.: Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 16 (4): 724-31, 1992 Jul-Aug.  [PUBMED Abstract]

  3. Koea JB, Shaw JH: Parathyroid cancer: biology and management. Surg Oncol 8 (3): 155-65, 1999.  [PUBMED Abstract]

  4. Clayman GL, Gonzalez HE, El-Naggar A, et al.: Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100 (5): 900-5, 2004.  [PUBMED Abstract]

  5. Munson ND, Foote RL, Northcutt RC, et al.: Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer 98 (11): 2378-84, 2003.  [PUBMED Abstract]

  6. Chow E, Tsang RW, Brierley JD, et al.: Parathyroid carcinoma--the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 41 (3): 569-72, 1998.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov